Sotos Syndrome — designated SoS, OMIM #117550, also known as Cerebral Gigantism or NSD1 Haploinsufficiency, a neurodevelopmental overgrowth disorder characterized by prenatal-onset tall stature, macrocephaly, advanced bone age, distinctive facial features, and intellectual disability affecting approximately 1 in 10,000–14,000 live births, caused by heterozygous loss-of-function pathogenic variants or deletions of NSD1 (nuclear receptor binding SET domain protein 1, mapped to chromosome 5q35) — a gene encoding a histone methyltransferase that catalyzes mono- and di-methylation of histone H3 at lysine 36 (H3K36me1 and H3K36me2), a chromatin modification associated with transcriptional elongation and gene body regulation that normally keeps growth-promoting gene programs (IGF2, IGFBP family, HMGA2) under appropriate epigenetic restraint during development; NSD1 H3K36 methylation establishes a chromatin landscape permissive for neurodevelopmental transcription factor programs while suppressing inappropriate activation of growth-promoting loci, so that NSD1 haploinsufficiency produces simultaneous dysregulation of growth gene programs (explaining the overgrowth and advanced bone age) and disruption of the neurodevelopmental transcription factor cascade (explaining the intellectual disability and behavioral phenotype); the molecular mechanisms producing Sotos Syndrome include heterozygous intragenic NSD1 point mutations, frameshift mutations, nonsense mutations, or splice-site mutations (most common in European populations), microdeletion of the 5q35 region encompassing NSD1 (more common in Japanese populations and detectable by chromosomal microarray or FISH), and rarely intragenic deletions or duplications detected by MLPA; the clinical phenotype includes the characteristic overgrowth triad of tall stature (consistently greater than 2 standard deviations above the mean throughout childhood), macrocephaly, and advanced bone age; the distinctive facial gestalt of prominent forehead with high frontal hairline, downslanting palpebral fissures, malar flushing, pointed chin, and high-arched palate that is most recognizable in early childhood and becomes less distinctive in adolescence; intellectual disability ranging from mild to moderate (with IQ typically 40–90) affecting all domains of adaptive functioning; a behavioral phenotype of irritability, anxiety, temper tantrums, and autistic traits in approximately 20% of individuals; epilepsy in approximately 50% (most commonly febrile seizures in early childhood and generalized epilepsy with valproate or levetiracetam-responsive seizures in later childhood); structural cardiac defects in approximately 20% (ventricular septal defect, atrial septal defect, patent ductus arteriosus, pulmonary stenosis); an elevated cancer risk (Wilms tumor, hepatoblastoma, teratoma, acute myeloid and lymphoid leukemia) that requires prospective oncology surveillance; strabismus and other ophthalmological abnormalities; and endocrine implications of the advanced bone age (which can compress final adult height if not identified and managed); no FDA-approved disease-modifying therapy currently exists, with management consisting of oncology surveillance protocols, seizure management with valproate or levetiracetam, growth monitoring with referral to endocrinology for advanced bone age management, behavioral therapies targeting anxiety and irritability, developmental and educational support through individualized education programs, speech-language therapy, occupational therapy, and physical therapy.
Sotos Syndrome technology platforms — encompassing the molecular genetics laboratories where NSD1 sequencing, chromosomal microarray, FISH, and MLPA establish the NSD1 pathogenic variant and enable genetic counseling (Sotos Syndrome is predominantly de novo with low recurrence risk, though familial cases with autosomal dominant inheritance have been documented), the pediatric neurology platforms where seizure management with AS-appropriate antiepileptic drugs is coordinated across the heterogeneous Sotos epilepsy phenotype (febrile seizures in toddlers, generalized epilepsy in school-age children, breakthrough seizures with growth-related AED dose adjustments), the oncology surveillance platforms executing the Sotos-specific tumor surveillance protocol (renal ultrasound every 3–6 months until age 7 for Wilms tumor detection; AFP every 3 months until age 4 for hepatoblastoma; annual CBC for acute leukemia surveillance), the growth monitoring platforms tracking height velocity on NSD1-specific growth charts with bone age radiograph scheduling and endocrinology referral coordination, the cardiac monitoring platforms coordinating echocardiographic surveillance for structural defects and cardiology follow-up for the 20% of individuals with cardiac anomalies, the behavioral health and developmental pediatric platforms managing anxiety, irritability, and autistic traits while coordinating individualized education programs and adaptive behavior services, and the rare disease registries collecting natural history data — must maintain the availability and performance standards required by the oncology surveillance urgency (pediatric Wilms tumor and hepatoblastoma have narrow imaging-detectable windows before becoming clinically apparent, and delayed detection correlates with worse tumor stage and outcome), the seizure management precision needed across the childhood epilepsy phenotype, the growth monitoring continuity essential for identifying advanced bone age early enough for endocrine intervention to influence final height, and the cardiac monitoring coordination required for the structural defects present in 20% of Sotos individuals. This guide explains why Sotos Syndrome tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the oncology surveillance imperative, seizure management precision, growth monitoring continuity, cardiac safety requirements, and behavioral coordination needs of modern Sotos Syndrome care.
Why Sotos Syndrome Tech Platforms Require Specialized Monitoring Attention
Sotos Syndrome management is defined by several clinically urgent platform requirements: the oncology surveillance imperative — Wilms tumor (nephroblastoma) occurring in Sotos Syndrome presents in the same age range (peak incidence ages 1–7) as sporadic Wilms tumor, where the renal ultrasound surveillance protocol detecting sub-clinical tumor at an early resectable stage before contralateral involvement or metastatic spread represents the primary intervention capable of altering tumor staging and survival outcomes; hepatoblastoma AFP surveillance for the first four years of life similarly detects presymptomatic hepatoblastoma when resection alone may be curative; and the CBC-based leukemia surveillance must be consistently executed to detect early-stage acute leukemia before symptomatic bone marrow failure; the advanced bone age management urgency — advanced bone age, if identified late, constrains the window for endocrine consultation and growth hormone assessment that might influence final height, making bone age radiograph scheduling and growth velocity tracking a clinically time-sensitive platform requirement; the seizure management precision requirement — Sotos epilepsy spans febrile seizures in toddlers requiring rectal or intranasal rescue medication and parent seizure action plans through generalized epilepsy in school-age children requiring valproate or levetiracetam with therapeutic drug monitoring and hepatic safety monitoring on valproate; and the cardiac monitoring coordination requirement for the 20% of Sotos individuals with structural cardiac anomalies who require echocardiographic baseline assessment and cardiology follow-up.
Oncology surveillance platforms protect against delayed Wilms tumor, hepatoblastoma, and leukemia detection. Renal ultrasound, AFP, and CBC surveillance protocols must be consistently executable. Monitor oncology surveillance platforms at 1-minute intervals during clinical hours.
Growth monitoring platforms track tall stature velocity and advanced bone age against NSD1-specific charts. Missed growth assessments or bone age scheduling failures delay endocrine consultation. Monitor growth platforms at 1-minute intervals during clinical hours.
Epilepsy management platforms coordinate seizure type characterization and AED management. Valproate therapeutic drug monitoring and hepatic safety monitoring require consistent laboratory access. Monitor epilepsy platforms at 1-minute intervals during clinical hours.
Cardiac monitoring platforms coordinate echocardiographic surveillance for structural defects. The 20% of Sotos individuals with cardiac anomalies require cardiology follow-up continuity. Monitor cardiac platforms at 1-minute intervals during clinical hours.
Behavioral health and developmental platforms coordinate IEP, therapy, and anxiety or ADHD management. Platform failures interrupt educational coordination and behavioral intervention continuity. Monitor behavioral platforms at 2-minute intervals during business hours.
What to Monitor on a Sotos Syndrome Tech Platform
Oncology Surveillance — Wilms Tumor, Hepatoblastoma, and Leukemia
Monitor renal ultrasound surveillance scheduling and result records (bilateral renal ultrasound every 3–6 months from diagnosis until age 7 — detecting Wilms tumor at a stage where nephrectomy alone provides excellent prognosis; ultrasound result review with nephroblastoma screening radiologist; abnormal finding escalation to pediatric oncology; Sotos-specific surveillance cessation protocol at age 7 when Wilms tumor risk returns to population baseline), AFP surveillance records (serum alpha-fetoprotein every 3 months from diagnosis until age 4 — hepatoblastoma detection with age-appropriate AFP reference ranges accounting for physiologic AFP elevation in infancy; AFP trend documentation; escalation protocol for rising AFP values), CBC surveillance records (complete blood count annually from early childhood — screening for leukopenia, thrombocytopenia, or blast cells suggesting acute leukemia; CBC result review with hematology consultation criteria for abnormal findings), and oncology surveillance calendar automation records (automated reminder and scheduling system ensuring that the 3–6-month renal ultrasound, 3-month AFP, and annual CBC surveillance intervals are consistently maintained without relying solely on family recall) at 1-minute intervals during clinical hours. Alert immediately — oncology surveillance platform failures during the scheduled 18-month renal ultrasound for a 2-year-old NSD1-confirmed Sotos male — where a renal mass that will be palpable at his 24-month primary care visit was visible at 2.5 cm on last ultrasound six months ago and could have been detected at a smaller stage if the current surveillance ultrasound had been completed on schedule — make platform-related scheduling failures a direct oncology safety concern.
Growth Monitoring — Height Velocity and Advanced Bone Age
Monitor height and weight measurement records (serial anthropometric measurements plotted on NSD1-specific Sotos growth charts — height velocity in cm/year; weight for height; head circumference plotted on macrocephaly-aware chart; deviation from the Sotos growth chart 90th percentile flagged for endocrine review), bone age scheduling and result records (annual bone age radiograph — left hand and wrist X-ray; Greulich and Pyle or Tanner-Whitehouse bone age reading; bone age advance relative to chronological age documented in years; bone age greater than 2 years advanced triggers endocrine consultation; bone age radiograph cessation when growth plates have closed), endocrinology referral records (growth hormone secretion assessment for Sotos individuals where advanced bone age significantly constrains projected final height; endocrinology consultation records; IGF-1 and IGFBP-3 measurement; growth hormone stimulation test records where indicated), and auxological trajectory prediction records (final height prediction by bone age-adjusted formula; comparison to parental target height; documentation of projected height shortfall attributable to advanced bone age) at 1-minute intervals during clinical hours. Alert immediately — growth platform failures preventing bone age radiograph scheduling for a 5-year-old Sotos female whose 18-month bone age advance was documented at her last visit and whose endocrinology consultation was initiated — where a subsequent bone age radiograph at the recommended 12-month interval is overdue and could show further advance requiring modification of the projected final height assessment and endocrine management plan.
Epilepsy Management — Seizure Type and AED Protocol
Monitor seizure diary records (parental seizure diary — seizure type classification in Sotos context: febrile seizures in early childhood vs. generalized unprovoked seizures vs. absence seizures; seizure frequency; seizure duration; AED response assessment; breakthrough seizure documentation), EEG records (baseline EEG; video-EEG for seizure type classification where diagnosis uncertain; ambulatory EEG for overnight or multi-day seizure burden assessment), AED management records (valproate: serum level 50–100 μg/mL therapeutic monitoring; hepatic transaminase, bilirubin, and ammonia monitoring on valproate initiation and at least twice yearly; platelet count monitoring; valproate dose adjustment for weight-based dosing in a tall-for-age child; levetiracetam: dose, behavioral adverse effects including irritability and aggression which are particularly significant in a Sotos individual with baseline irritability phenotype; AED adherence monitoring), febrile seizure rescue medication records (rectal diazepam or intranasal midazolam prescription and refill management; seizure action plan for parents and school personnel; 911 guidance for prolonged febrile seizures), and neurology follow-up records (annual neurology review for seizure-controlled patients; EEG review; AED dose optimization with growth-based dose recalculation) at 1-minute intervals during clinical hours. Alert immediately — epilepsy platform failures preventing the processing of valproate trough level and LFT results for a 7-year-old Sotos female who was started on valproate 3 months ago for generalized epilepsy — where the valproate hepatic monitoring required at 3-month intervals following initiation is clinically time-critical for identifying early valproate hepatotoxicity at a stage where dose reduction or discontinuation can prevent progression to fulminant hepatic failure.
Cardiac Monitoring — Structural Defects in 20%
Monitor echocardiogram records (baseline echocardiogram at Sotos diagnosis — structural anomaly identification: ventricular septal defect, atrial septal defect, patent ductus arteriosus, pulmonary stenosis, bicuspid aortic valve; echocardiogram report review by pediatric cardiologist; cardiac anatomy documentation), cardiology follow-up records (annual cardiology review for Sotos individuals with documented structural defects — lesion progression assessment; intervention threshold monitoring for VSD, ASD, or pulmonary stenosis; endocarditis prophylaxis guidance), cardiac symptom diary records (exercise tolerance documentation; dyspnea on exertion; palpitations; syncope — clinical flags for accelerating cardiac review frequency), and ECG records (baseline ECG; conduction interval assessment; arrhythmia screening in symptomatic Sotos individuals) at 1-minute intervals during clinical hours. Alert immediately — cardiac monitoring platform failures preventing the retrieval of the echocardiogram report for a 4-year-old Sotos male with a previously documented perimembranous ventricular septal defect — where the pediatric cardiologist reviewing his annual follow-up visit needs to compare current echocardiographic measurements with the prior study to determine whether the defect has shown spontaneous closure or is showing hemodynamic significance requiring intervention planning.
Behavioral Management and Developmental Records
Monitor behavioral management diary records (behavioral incident log — anxiety episodes, irritability and temper tantrums; ASD-associated behavioral documentation; ADHD-like inattention and impulsivity records; behavioral intervention response; medication log for behavioral pharmacotherapy: SSRI for anxiety, stimulant or guanfacine for ADHD; behavioral adverse effect monitoring), developmental records (cognitive testing — IQ assessment every 2–3 years using WPPSI or WISC standardized tools; adaptive behavior testing using Vineland-3 or ABAS-3; speech and language assessment — expressive and receptive language; occupational therapy records — fine motor, ADL skills; physical therapy records — gross motor, gait), IEP coordination records (annual IEP meeting records; educational placement documents; related services authorization — SLP, OT, PT, behavioral support), autism assessment records (ADOS-2, ADI-R in Sotos individuals with autistic traits for formal ASD co-diagnosis and service access), and ophthalmology records (annual eye exam — strabismus assessment; refractive error; amblyopia treatment records) at 2-minute intervals during business hours. Alert on sustained failures — behavioral platform failures interrupting the IEP coordination for a 9-year-old Sotos male transitioning from elementary to middle school — where placement records, behavioral support plan documentation, and therapy authorization are time-sensitive for the enrollment process.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Sotos Syndrome management coordinates across molecular genetics (NSD1 characterization), pediatric oncology (Wilms tumor and hepatoblastoma surveillance), pediatric hematology (leukemia surveillance), pediatric neurology (epilepsy), endocrinology (advanced bone age, growth), cardiology (structural cardiac defects), developmental pediatrics, behavioral health, speech-language pathology, occupational therapy, physical therapy, ophthalmology, and special education — authentication failures block every specialist required to maintain the oncology surveillance schedule, seizure management, and growth monitoring continuity that define Sotos Syndrome clinical management.
SSL Certificates
Monitor SSL certificate expiry across all oncology surveillance scheduling systems, growth monitoring platforms, epilepsy management systems, cardiac monitoring platforms, molecular genetics portals, and behavioral health systems. Certificate errors disrupting oncology surveillance calendar access carry direct patient safety implications for a population with elevated pediatric cancer risk requiring consistent time-interval surveillance.
HIPAA and Genomic Privacy Considerations for Sotos Syndrome
Sotos Syndrome technology platforms handle NSD1 pathogenic variant results, chromosomal microarray data (for deletion cases), and oncology surveillance imaging findings that collectively constitute sensitive protected health information requiring HIPAA Privacy Rule protections. The predominantly de novo NSD1 pathogenic variant carries low recurrence risk for unaffected parents, but familial cases with autosomal dominant inheritance require careful genetic counseling records management with appropriate disclosure controls for extended family members.
Pediatric oncology surveillance records — renal ultrasound results, AFP values, and CBC findings — must be managed with clear authorization controls distinguishing the minor patient's legal guardian access from unauthorized third-party access. Sotos Syndrome individuals with intellectual disability require legal guardianship documentation maintained across all care platforms when they reach the age of majority, with clear procedures for authorized representative access and prohibition of unauthorized access to oncology surveillance records and behavioral health documentation.
Alerting Strategy for Sotos Syndrome Tech Platforms
Immediate clinical-hours alerting for oncology surveillance platforms: Renal ultrasound, AFP, and CBC surveillance intervals are time-critical for pediatric tumor detection; scheduling system failures during the surveillance window carry direct oncology safety implications.
Immediate clinical-hours alerting for epilepsy management platforms: Valproate therapeutic drug monitoring and hepatic safety monitoring require laboratory access at defined intervals; AED management platform failures during monitoring intervals carry patient safety implications.
Immediate clinical-hours alerting for growth monitoring platforms: Bone age radiograph scheduling and height velocity tracking are time-sensitive for endocrine consultation windows; growth platform failures delay advanced bone age identification and final height projection.
Immediate clinical-hours alerting for cardiac monitoring platforms: Echocardiographic surveillance and cardiology follow-up for structural defects require consistent scheduling access.
Immediate 24/7 alerting for authentication platforms: Multi-specialty coordination across oncology, neurology, endocrinology, and cardiology requires continuous authentication availability.
Sustained-failure alert (10–15 minutes): Behavioral health coordination, developmental records, IEP management, ophthalmology, and rare disease registry platforms.
30-day advance warning: SSL certificates across all oncology surveillance, epilepsy management, cardiac monitoring, growth, and molecular testing platforms.
Vigilmon's multi-region monitoring confirms Sotos platform availability from the geographic regions where NSD1 molecular testing laboratories, pediatric Wilms tumor surveillance programs, pediatric neurology and epilepsy clinics, and Sotos specialty centers concentrate.
Status Page for Sotos Syndrome Care Team Communication
A real-time status page gives NSD1 molecular geneticists confirming pathogenic variant, pediatric oncologists coordinating Wilms tumor surveillance, pediatric neurologists managing Sotos epilepsy, endocrinologists assessing advanced bone age, pediatric cardiologists monitoring structural defects, and caregivers navigating multi-specialty coordination across oncology, neurology, endocrinology, and cardiology immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in oncology surveillance backup procedures, epilepsy clinic downtime protocols, growth monitoring platform emergency procedures, and cardiac monitoring downtime documentation.
Vigilmon Setup for Sotos Syndrome Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Renal ultrasound surveillance (Wilms tumor, every 3–6 months until age 7) | 1 min | Slack + PagerDuty (clinical hours) | | AFP surveillance (hepatoblastoma, every 3 months until age 4) | 1 min | Slack + PagerDuty (clinical hours) | | CBC surveillance (leukemia, annually) | 1 min | Slack + PagerDuty (clinical hours) | | Growth monitoring (height velocity, NSD1 growth chart) | 1 min | Slack + PagerDuty (clinical hours) | | Bone age radiograph scheduling (annual until growth plates close) | 1 min | Slack + PagerDuty (clinical hours) | | Endocrinology referral and IGF-1 monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Seizure diary and EEG records | 1 min | Slack + PagerDuty (clinical hours) | | Valproate level and LFT monitoring | 1 min | Slack + PagerDuty (clinical hours) | | AED management (levetiracetam, valproate) | 1 min | Slack + PagerDuty (clinical hours) | | Rescue medication and seizure action plan | 1 min | Slack + PagerDuty (24/7) | | Echocardiogram and cardiology follow-up | 1 min | Slack + PagerDuty (clinical hours) | | NSD1 molecular genetics (sequencing, microarray) | 1 min | Slack + PagerDuty (lab hours) | | Behavioral management and IEP coordination | 2 min | Slack (business hours) | | Ophthalmology (strabismus, refractive error) | 2 min | Slack (business hours) | | Rare disease registry and natural history study | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure renal ultrasound surveillance scheduling with immediate clinical-hours alerting — the highest patient safety priority in the Sotos oncology surveillance ecosystem
- Add AFP surveillance platforms with immediate clinical-hours alerting
- Configure CBC surveillance platforms with immediate clinical-hours alerting
- Add growth monitoring platforms (height velocity, NSD1 growth chart) with immediate clinical-hours alerting
- Configure bone age radiograph scheduling with immediate clinical-hours alerting
- Add endocrinology referral and IGF-1 monitoring platforms with immediate clinical-hours alerting
- Configure seizure diary and EEG platforms with immediate clinical-hours alerting
- Add valproate level and LFT monitoring with immediate clinical-hours alerting
- Configure AED management platforms with immediate clinical-hours alerting
- Add rescue medication and seizure action plan platforms with 24/7 immediate alerting
- Configure echocardiogram and cardiology follow-up platforms with immediate clinical-hours alerting
- Add NSD1 molecular genetics platforms with immediate laboratory-hours alerting
- Configure behavioral management and IEP coordination platforms with sustained-failure alerting
- Add ophthalmology platforms with sustained-failure alerting
- Configure rare disease registry platforms with sustained-failure alerting
- Enable SSL certificate monitoring across all oncology surveillance, epilepsy, growth, cardiac, and molecular testing platforms
- Add the status page URL to oncology surveillance backup procedures, epilepsy clinic downtime protocols, and cardiac monitoring emergency documentation
Conclusion
Sotos Syndrome technology platforms are embedded in clinical decisions where oncology surveillance platform availability during the 18-month renal ultrasound appointment for a 2.5-year-old NSD1-confirmed Sotos female — when the pediatric radiology system scheduling the bilateral renal ultrasound required at her 3–6-month surveillance interval has experienced an overnight downtime affecting the scheduling workflow and the ultrasound cannot be completed on the planned date — directly affects the probability of detecting a presymptomatic Wilms tumor at a localized, unilateral, stage I–II lesion where surgical resection alone provides excellent long-term survival outcomes compared with the advanced stage outcome that correlates with delayed detection; where valproate hepatic monitoring platform availability for a 7-year-old Sotos male who has been on valproate for generalized epilepsy for 3 months — when the laboratory platform reporting the valproate trough level and liver function tests required at the 3-month post-initiation interval is temporarily unavailable and the results cannot be reviewed by the neurologist scheduling the follow-up appointment — prevents the early identification of transaminase elevation at a stage where dose reduction or alternative AED substitution would interrupt the hepatotoxicity cascade before clinical jaundice, coagulopathy, or fulminant hepatic failure; and where growth monitoring platform availability during the annual bone age assessment for a 6-year-old Sotos male with 18-month bone age advance documented at his prior visit — when the radiograph scheduling system is unavailable and the annual bone age X-ray cannot be ordered during the endocrinology appointment — delays the bone age data that informs the endocrinologist's decision about whether the projected final height shortfall attributable to advanced bone age has crossed the threshold warranting growth hormone evaluation, with the clinically meaningful consequence that this decision cannot be made during the appointment window when the family traveled to the specialty center. A Sotos oncology surveillance platform unavailable during a renal ultrasound surveillance appointment, a valproate hepatic monitoring platform interrupted at the 3-month post-initiation interval, a bone age scheduling system unavailable during the endocrinology visit — these are not IT incidents. They are clinical disruptions in the management of a disorder whose cancer surveillance requires absolute schedule adherence, whose valproate management requires interval hepatic monitoring, and whose advanced bone age management requires consistent bone age radiograph access at defined intervals.
Uptime monitoring gives Sotos Syndrome tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to NSD1 molecular testing laboratories, pediatric Wilms tumor surveillance programs, pediatric neurology and epilepsy clinics, endocrinology practices, pediatric cardiology programs, and compliance auditors that platform operational reliability matches the oncology surveillance urgency, seizure management precision, advanced bone age monitoring continuity, and cardiac safety requirements of modern Sotos Syndrome care.
Start monitoring your Sotos Syndrome care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #sotos #syndrome #NSD1 #cerebral #gigantism #haploinsufficiency #H3K36 #methyltransferase #overgrowth #macrocephaly #WilmsTumor #hepatoblastoma #oncology #surveillance #epilepsy #valproate #levetiracetam #bonage #growth #endocrinology #cardiac #neurodevelopmental #HIPAA #healthtech #digitalhealth #uptime #sre